Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$11.49 USD
-0.15 (-1.29%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.53 +0.04 (0.35%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NTLA 11.49 -0.15(-1.29%)
Will NTLA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NTLA
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
Other News for NTLA
NTLA Awards Inducement Grant Amid Employment Expansion
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA ...
Intellia Therapeutics announces employee inducement grants
Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options